- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07861347
Emulation of the KEYNOTE177 Trial Using Specialty Oncology Electronic Health Records Databases
This observational trial emulation aims to reproduce the KEYNOTE-177 trial (NCT02563002) using real-world specialty oncology electronic health record data and to assess the concordance between the original and emulated treatment effect estimates for overall survival (OS). KEYNOTE-177 was a phase III, open-label, randomized trial comparing first-line pembrolizumab with 5-fluorouracil-based chemotherapy, with or without bevacizumab or cetuximab, in patients with MSI-H or dMMR metastatic colorectal cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Randomized controlled trials (RCTs) are generally regarded as the gold standard for establishing the efficacy of medical products. Real-world data (RWD) can complement evidence from RCTs, but valid non-interventional oncology studies require suitable data, study designs, and analysis methods. Building on the RCT DUPLICATE initiative, the EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) project aims to emulate 12 randomized oncology trials using multiple electronic health record data sources.
The purpose of this protocol is to describe the emulation of KEYNOTE-177 (NCT02563002). KEYNOTE-177 was a phase III, open-label, randomized trial comparing first-line pembrolizumab with 5-fluorouracil-based chemotherapy, with or without bevacizumab or cetuximab, in patients with MSI-H or dMMR metastatic colorectal cancer.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Somerville, Massachusetts, Estados Unidos, 02145
- Brigham and Women's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults with metastatic colorectal cancer who initiated first-line pembrolizumab or 5-fluorouracil-based chemotherapy.
Descripción
Inclusion Criteria:
- Age 18 years or older at first-line study regimen initiation.
- Metastatic colorectal cancer documented in a specialty oncology electronic health record.
- Initiation of pembrolizumab or 5-fluorouracil-based chemotherapy, with or without bevacizumab or cetuximab, as first-line treatment for metastatic disease.
- Confirmed dMMR or MSI-H status for chemotherapy initiators; pembrolizumab initiators were presumed to have dMMR or MSI-H disease based on the treatment indication.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the database.
Exclusion Criteria:
- Prior systemic treatment for metastatic colorectal cancer.
- Chemotherapy within 6 months before study regimen initiation.
- Use of an investigational agent within 4 weeks before study regimen initiation.
- Active autoimmune disease requiring systemic treatment within 2 years before study regimen initiation.
- Known active central nervous system or meningeal metastases.
- Prior immune checkpoint inhibitor treatment.
- Another primary malignancy within 5 years before study regimen initiation, except nonmelanoma skin cancer or cervical carcinoma in situ.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: RETROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Initiation of pembrolizumab
|
Observed initiation of first-line pembrolizumab for MSI-H or dMMR metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study. |
|
Initiation of 5-fluorouracil-based chemotherapy
|
Observed initiation of first-line 5-fluorouracil-based chemotherapy, with or without bevacizumab or cetuximab, for MSI-H or dMMR metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to all-cause mortality (overall survival)
Periodo de tiempo: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Hazard ratio (95% CI) |
From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Shirley V Wang, PhD, ScM, Brigham and Women's Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2022P002556-ENC-KEYNOTE177
- 75F40122C00181 (Otro número de subvención/financiamiento: Food and Drug Administration)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .